CN1315822C - 具有vegf抑制活性的喹啉衍生物 - Google Patents

具有vegf抑制活性的喹啉衍生物 Download PDF

Info

Publication number
CN1315822C
CN1315822C CNB018139000A CN01813900A CN1315822C CN 1315822 C CN1315822 C CN 1315822C CN B018139000 A CNB018139000 A CN B018139000A CN 01813900 A CN01813900 A CN 01813900A CN 1315822 C CN1315822 C CN 1315822C
Authority
CN
China
Prior art keywords
alkyl
ethyl
cyano
quinoline
propoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018139000A
Other languages
English (en)
Chinese (zh)
Other versions
CN1446212A (zh
Inventor
L·F·A·亨内奎恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1446212A publication Critical patent/CN1446212A/zh
Application granted granted Critical
Publication of CN1315822C publication Critical patent/CN1315822C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB018139000A 2000-08-09 2001-08-08 具有vegf抑制活性的喹啉衍生物 Expired - Fee Related CN1315822C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402254.7 2000-08-09
EP00402254 2000-08-09

Publications (2)

Publication Number Publication Date
CN1446212A CN1446212A (zh) 2003-10-01
CN1315822C true CN1315822C (zh) 2007-05-16

Family

ID=8173805

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018139000A Expired - Fee Related CN1315822C (zh) 2000-08-09 2001-08-08 具有vegf抑制活性的喹啉衍生物

Country Status (14)

Country Link
US (2) US7371765B2 (enExample)
EP (1) EP1313726A1 (enExample)
JP (1) JP2004505964A (enExample)
KR (1) KR20030036686A (enExample)
CN (1) CN1315822C (enExample)
AU (2) AU7653601A (enExample)
BR (1) BR0113056A (enExample)
CA (1) CA2415469A1 (enExample)
IL (2) IL153947A0 (enExample)
MX (1) MXPA03000252A (enExample)
NO (1) NO326315B1 (enExample)
NZ (1) NZ523358A (enExample)
WO (1) WO2002012226A1 (enExample)
ZA (1) ZA200300217B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3893026B2 (ja) 1999-02-10 2007-03-14 アストラゼネカ アクチボラグ 血管形成阻害剤としてのキナゾリン誘導体
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
DE60112268T2 (de) 2000-03-06 2006-05-24 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
ATE334973T1 (de) * 2000-04-07 2006-08-15 Astrazeneca Ab Chinazolinverbindungen
JP4608215B2 (ja) * 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
MXPA05004858A (es) 2002-11-04 2005-07-22 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina de src.
AU2004309166B2 (en) * 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
AU2008202205B2 (en) * 2003-12-23 2009-09-10 Pfizer Inc. Novel quinoline derivatives
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
US7928226B2 (en) 2005-08-08 2011-04-19 Agouron Pharmaceuticals Inc. Salts and polymorphs of a VEGF-R inhibitor
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
JP2011526892A (ja) 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
CN101723894B (zh) * 2009-12-03 2011-12-28 南京大学 N-喹啉酰胺类衍生物及其制法与用途
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
WO2014130612A1 (en) 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2654100T3 (es) 2013-02-21 2018-02-12 Glaxosmithkline Intellectual Property Development Limited Quinazolinas como inhibidores de quinasa
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN112028825B (zh) * 2015-04-07 2025-03-14 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
SG11202109111VA (en) 2019-02-27 2021-09-29 Univ California Azepino-indoles and other heterocycles for treating brain disorders
US12508258B2 (en) 2020-01-19 2025-12-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative for treating rheumatoid arthritis
MX2024007221A (es) 2021-12-15 2024-08-27 Delix Therapeutics Inc Psicoplastogenos sustituidos con fenoxi y benciloxi y sus usos.
CN120289432B (zh) * 2025-06-12 2025-09-05 上海健康医学院 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
EP0860433A1 (en) * 1995-11-07 1998-08-26 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
CN1237963A (zh) * 1996-09-25 1999-12-08 曾尼卡有限公司 抑制生长因子如vegf的作用的喹啉衍生物
WO2000018761A1 (en) * 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36256A (en) * 1862-08-19 Improvement in sewing-m ach ines
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL117620A0 (en) 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
KR100622323B1 (ko) 1996-10-01 2006-11-30 교와 핫꼬 고교 가부시끼가이샤 질소-함유헤테로고리화합물
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
EP0860433A1 (en) * 1995-11-07 1998-08-26 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
CN1237963A (zh) * 1996-09-25 1999-12-08 曾尼卡有限公司 抑制生长因子如vegf的作用的喹啉衍生物
WO2000018761A1 (en) * 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Also Published As

Publication number Publication date
IL153947A (en) 2008-12-29
AU7653601A (en) 2002-02-18
IL153947A0 (en) 2003-07-31
NO20030625L (no) 2003-02-07
KR20030036686A (ko) 2003-05-09
AU2001276536B2 (en) 2007-01-04
BR0113056A (pt) 2003-07-08
MXPA03000252A (es) 2003-06-06
WO2002012226A1 (en) 2002-02-14
AU2001276536B9 (en) 2002-02-18
NZ523358A (en) 2004-09-24
NO326315B1 (no) 2008-11-10
EP1313726A1 (en) 2003-05-28
US20030199491A1 (en) 2003-10-23
JP2004505964A (ja) 2004-02-26
US7371765B2 (en) 2008-05-13
CA2415469A1 (en) 2002-02-14
US20080312273A1 (en) 2008-12-18
CN1446212A (zh) 2003-10-01
NO20030625D0 (no) 2003-02-07
ZA200300217B (en) 2004-04-08

Similar Documents

Publication Publication Date Title
CN1315822C (zh) 具有vegf抑制活性的喹啉衍生物
JP4651576B2 (ja) 血管形成阻害剤としてのキナゾリン誘導体
US6887874B2 (en) Cinnoline compounds
CN100376567C (zh) 作为vegf抑制剂的喹唑啉衍生物
US20060148819A1 (en) Chemical compounds
AU2001276536A1 (en) Quinoline derivatives having vegf inhibiting activity
AU2001276521A1 (en) Cinnoline compounds
EP2292615A1 (en) Quinazoline compounds
ZA200102655B (en) Quinazoline derivatives.
AU2001279938A1 (en) Indole, azaindole and indazole derivatives having VEGF inhibiting activity
CN1863794B (zh) 作为血管生成抑制剂的喹唑啉衍生物
HK1139675A (en) Quinazoline compounds
HK1154586A (en) Quinazoline compounds
HK1076104B (en) Intermediate compounds, their use in the preparation of quinazoline derivatives and methods for their preparation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070516

Termination date: 20090908